Group 1 - On September 17, Lisheng Pharmaceutical's stock fell by 1.20%, with a trading volume of 87.40 million yuan [1] - The financing data shows that on the same day, Lisheng Pharmaceutical had a financing purchase amount of 8.10 million yuan and a financing repayment of 16.16 million yuan, resulting in a net financing outflow of 8.06 million yuan [1] - As of September 17, the total balance of margin trading for Lisheng Pharmaceutical was 310 million yuan, accounting for 5.21% of its circulating market value, which is above the 90th percentile of the past year [1] Group 2 - As of August 20, the number of shareholders of Lisheng Pharmaceutical was 31,200, a decrease of 0.39% from the previous period, while the average circulating shares per person increased by 0.39% to 8,017 shares [2] - For the first half of 2025, Lisheng Pharmaceutical achieved an operating income of 732 million yuan, a year-on-year decrease of 1.76%, while the net profit attributable to the parent company was 343 million yuan, a year-on-year increase of 235.04% [2] Group 3 - Since its A-share listing, Lisheng Pharmaceutical has distributed a total of 1.261 billion yuan in dividends, with 255 million yuan distributed in the last three years [3] - As of June 30, 2025, Dazheng Jingheng Mixed A (090019) has exited the list of the top ten circulating shareholders of Lisheng Pharmaceutical [3]

Group 1 - The company announced a change of registered address for its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., due to operational development needs [1] - The new registered address is located at the Economic and Technological Development Zone in Wangcheng, Changsha City, Hunan Province [1] - The company has completed the relevant industrial and commercial registration procedures and obtained a new business license approved by the Wangcheng Economic and Technological Development Zone Management Committee [1] Group 2 - Hunan Sailong Pharmaceutical Co., Ltd. is a limited liability company with a registered capital of 28 million yuan [1] - The company was established on April 13, 2007, and its legal representative is Long Zhixiang [1] - The business scope includes the production and sales of various pharmaceutical products, including sterile raw materials and medical devices, as well as research and development activities [1]